Background. Antiretroviral treatment (ART) programs in sub-Saharan Africa have for many years included lamivudine as the sole hepatitis B virus (HBV) inhibitor. Long-term outcomes and the effects of introducing tenofovir as part of ART in these populations have not been characterized.
In Western cohorts, HIV/HBV-coinfected patients receiving lamivudine as the sole HBV-active antiviral agent showed a high risk of virologic breakthrough with emergence of HBV drug resistance and progression of liver fibrosis [3] [4] [5] [6] .
In sub-Saharan Africa (SSA), 6%-25% of HIV-infected people are chronically coinfected with HBV [7] . Due to lack of routine HBV screening and limited availability of tenofovir, ART programs have for many years been "HBV-blind" and contained lamivudine as the sole HBV-active agent. Limited data suggest that levels of HBV replication and rates of emergent HBV drug resistance during lamivudine exposure vary geographically across SSA [8] [9] [10] [11] [12] [13] [14] . Data on the associated indices of liver disease are scarce. Following revised recommendations from the World Health Organization (WHO) [2] , national ART programs in SSA are increasingly adopting tenofovir for first-line therapy, although access remains far from universal. In Western HBV-infected cohorts with and without HIV, therapy with tenofovir has been shown to result in regression of liver fibrosis [15] [16] [17] [18] , with histologic improvements documented after 1 year [17] and continuing at 5 years [16] . The extent to which tenofovir-containing ART can influence parameters of liver fibrosis in HIV/HBV-coinfected patients with long-term lamivudine exposure in SSA is unknown.
Transient elastography (TE) has been validated in Western cohorts for assessing liver disease of diverse etiologies, including chronic hepatitis B [19] , and provides a simple option for the noninvasive evaluation of liver fibrosis in resource-limited settings. Evidence from Burkina Faso [20] and The Gambia [21] indicates that TE has high concordance with histologically determined hepatic fibrosis among patients with HBV infection. Two studies from Nigeria [22] and Uganda [23] also reported that HIV infection, HBV infection, and HBV DNA levels were each predictive of high TE measurements. The first study included 16 HIV/HBV-coinfected patients, whereas the second analyzed 94 HIV/HBV-coinfected patients who were naive to ART.
In this study, we evaluated hepatic fibrosis using TE and correlated the findings with simultaneously measured markers of liver disease and HIV and HBV replication among coinfected patients attending for HIV care in Ghana. The study comprised a cross-sectional analysis of tenofovir-naive, lamivudine-experienced subjects, and a prospective analysis of lamivudine-experienced subjects who were assessed before and after introduction of tenofovir as part of ART.
METHODS

Study Population
HEPIK (Hepatitis B Infection in Kumasi) is a prospective study of HIV/HBV-coinfected adults based at the Komfo Anokye Teaching Hospital (KATH), Kumasi, Ghana. The study received ethics approval from the Kwame Nkrumah University of Science and Technology, Ghana, and started recruitment in October 2010. Participants gave written informed consent.
Transient Elastography and Sampling
TE was performed in July 2011 and July 2012 using portable equipment (Fibroscan, Ecosens, France). Valid TE measurements showed an interquartile range/median ratio (IQR/M) ≤0.30 or IQR/M >0.30 with median readings <7.1 kPa [24] . Interpretative cutoffs for histologically defined Metavir scores were 5.9 kPa (F2, moderate fibrosis), 7.6 kPa (F3, advanced fibrosis), and 9.4 kPa (F4, cirrhosis), as determined for HIV/ HBV coinfection [25] . Blood samples were collected at the time of TE. CD4 cell counts, full blood counts, and serum biochemistry were performed in the KATH diagnostic laboratory. Serum and plasma were stored at −80°C and shipped frozen to the United Kingdom for further testing. A random subset of 39 samples already tested for alanine aminotransferase (ALT) and aspartate aminotransferase (AST) at KATH were retested in the United Kingdom; results showed excellent agreement (Pearson correlation coefficient, r 2 0.927 and 0.967, respectively; P < .001, analysis of variance). The AST-to-platelet ratio index (APRI) and Fibrosis-4 (FIB-4) predictive scores were calculated from standard equations [26] .
HIV Status
Plasma HIV type 1 (HIV-1) RNA was quantified by RealTime HIV-1 assay (Abbott Diagnostics, UK). The lower limit of quantification (LLOQ) was 40 copies/mL. Samples with HIV-1 RNA >200 copies/mL underwent Sanger sequencing of HIV-1 reverse transcriptase (amino acids [aa] 1-323) and protease (aa 1-99) to detect drug resistance-associated mutations (RAMs) affecting the nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), nonnucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs), as described [27] . HIV-1 RNA load and drug resistance were assessed retrospectively. Virologic monitoring was not part of routine care at KATH, and ART failure was defined by clinical and immunologic parameters.
Hepatitis B, C, and D Virus Status
Serum hepatitis B surface antigen (HBsAg) was detected by Determine HBsAg (Alere); Determine-negative samples were retested by Murex HBsAg enzyme immunoassay (Abbott Diagnostics). Hepatitis B e antigen (HBeAg) and anti-HBe antibody were measured by Architect (Abbott Diagnostics). Plasma HBV DNA was quantified by real-time polymerase chain reaction (PCR) as described elsewhere (LLOQ, 14 IU/mL) [8] . Samples with HBV DNA >100 IU/mL underwent sequencing of the HBV polymerase gene (aa 1-344) as described previously [8] .
Real-time PCR was used to detect hepatitis C virus (HCV) RNA and hepatitis D virus (HDV) RNA (LLOQ, 50 IU/mL and 500 IU/mL, respectively). HDV antibody was measured by HDV total antibody DIA.PRO (Diagnostic Biomarkers, Italy). We did not rely on HCV antibody detection due to poor performance in this population [26] .
Statistical Analysis
The correlation between HIV-1 RNA and HBV DNA detection was assessed by Spearman rank correlation coefficient. 
RESULTS
Study Participants
Between October 2010 and July 2012, 1643 consecutive adults underwent HBsAg testing, and 230 (14.0%; [95% confidence Relative to the 133 subjects who attended, the 97 HBsAg-positive subjects excluded from this analysis were more likely to be female (62/106 [71.1%] vs 69/97 [58.5%]; P = .078), with a lower CD4 cell count (median, 402 vs 570 cells/µL; P < .001), but with no difference in age (median, 38 vs 40 years; P = .13).
Cross-sectional Analysis of Tenofovir-Naive Subjects Receiving Lamivudine
The characteristics of the study population are summarized in [25] .
b The HBV drug resistance analysis (HBV DNA >100 IU/mL) comprised 47 subjects, 44 of whom yielded a sequence. The median HBV DNA load was 7.4 (IQR, 6.2-8.4) vs 3.4 (IQR, 2.6-6.2) log 10 IU/mL in subjects with vs those without HBV RAMs (P < .001). HBV genotypes were E (n = 43) and A1 (n = 1). analogue mutations T215F, T215NSTY, and D67N + K70R + K219Q, respectively. No major PI RAMs were identified. After a median of 45 months of lamivudine, HBV DNA was <14 IU/mL in 52 of 106 (49.1%) subjects. Among subjects with detectable HBV DNA, 23 of 54 (42.6%) also had detectable HIV-1 RNA (Spearman ρ = 0.21; P = .033). Resistance testing was successful in 44 of 47 subjects with HBV DNA >100 IU/ mL. Overall, 31 of 106 (29.2%) subjects harbored ≥1 HBV RAM, comprising M204I or M204V in all cases, and commonly accompanied by ≥1 compensatory mutation (L80I, V173L, L180M) ( Table 2 ). The prevalence of M204I/V was 5.9% in 17 subjects with ≤18 months of lamivudine exposure, and 52.9% in 17 subjects with between 72 and 90 months of exposure (Figure 2) . HBeAg-positive subjects (30/106 [28.3%]) had higher HBV DNA levels, prevalence of HBV RAMs, ALT and AST levels, and APRI and FIB-4 scores than HBeAg-negative subjects, whereas their body mass index and platelet counts were lower ( Table 2) .
Median TE values were 5.7 kPa (IQR, 4.7-7.2 kPa) in the total population on lamivudine, 7.0 kPa (IQR, 5.5-9.5 kPa) in HBeAg-positive subjects, and 5.4 kPa (IQR, 4.5-6.9 kPa) in HBeAg-negative subjects (P = .001) ( Table 2) . By univariate analysis, longer duration of lamivudine exposure was associated with higher TE measurements. By multivariable analysis, 3 variables-higher HBV DNA load, higher AST levels, and lower platelet counts-were independently associated with increased liver stiffness ( Table 3 Tables 4 and 5 . There was no significant change in the proportion of subjects with HIV-1 RNA >40 copies/mL (25% at both T0 and T1) and >1000 copies/mL (16% at T0 vs 14% at T1). HBV DNA levels declined by a mean of -1.5 log 10 IU/mL (95% CI, -2.1 to -.9; P < .001), which reduced HBV DNA detection rates and proportions with HBV DNA >2000 IU/mL (Table 4) . HBV DNA levels declined by a mean of -4.3 log 10 IU/mL in subjects who at T0 were HBeAg positive (95% CI, -5.3 to -3.3; P < .001), and by a mean of -4.9 log 10 IU/ /L]).
mL in those who had HBV RAMs (95% CI, -5.7 to -4.1; P < .001) (Figure 3) . Five of 23 (21.7%) HBeAg-positive subjects lost HBeAg, and 1 acquired anti-HBe antibody at T1. There was no significant change in ALT and AST levels either overall or by HBeAg status (Supplementary Table 1 ). The mean change in TE values was −0.23 kPa (95% CI −.72 to .25; P = .097), and this reduced the proportion of subjects with TE scores >9.4 kPa (Figure 4) . The largest reductions in TE values were seen in those subjects that pretenofovir were HBeAg positive, had HBV DNA levels >2000 IU/mL, or TE measurements >7.6 kPa (Table 5) .
DISCUSSION
This study presents the first analysis of liver fibrosis by TE, and associated markers of liver disease and virologic status, among HIV/HBV-coinfected subjects with long-term lamivudine exposure in SSA, and is the first to analyze prospectively the effect of introducing tenofovir in such populations. At 14.0%, HBsAg seroprevalence in the Kumasi cohort was high, whereas HCV or HDV infection was rare. After nearly 4 years of lamivudinecontaining ART, more than half of patients had persistent HBV replication, one-third had HBV DNA levels >2000 IU/ mL, nearly one-third had HBV drug resistance, and 1 in 8 had TE measurements consistent with advanced fibrosis. HBV responses to the introduction of tenofovir, while usually continuing lamivudine, were highly encouraging, with marked reductions in HBV DNA levels and reduced TE measurements in those with higher baseline measurements. The virologic expression of HIV/HBV coinfection varies across SSA, and the underlying determinants are poorly understood. Observational studies suggest mild outcomes in cohorts receiving lamivudine-containing ART without tenofovir in Kenya, Cameroon, and southern Africa, with high rates of HBV DNA suppression and a low risk of HBV drug resistance [9] [10] [11] [12] [13] [14] . In contrast, coinfected patients in Malawi show poor HBV DNA suppression and rapid emergence of HBV drug resistance after starting lamivudine [8] . Previous reports analyzed cohorts with 12-24 months of lamivudine exposure. In Kumasi, after a median of 45 months of treatment with lamivudine, HBV DNA suppression rates were 9% in HBeAg-positive subjects and 63% HBeAg-negative subjects, and HBV DNA load, prevalence of HBV drug resistance, and liver stiffness were progressively higher in subjects with longer duration of exposure. The prevalence of HBV drug resistance was 29% overall, increasing from 6% in subjects with ≤18 months of lamivudine exposure to 53% in those treated for between 72 and 90 months. As expected [8] , HBeAg status and HBV DNA levels influenced the rates of HBV resistance.
The HBV mutation patterns were those classically associated with prolonged lamivudine exposure, primarily M204I/V plus Abbreviations: ALT, alanine aminotransferase; ART, antiretroviral therapy; AST, aspartate aminotransferase; BMI, body mass index; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; HIV, human immunodeficiency virus; IQR, interquartile range; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor; RAM, resistance-associated mutation; T0, July 2011; T1, July 2012; UD, undetectable (HIV-1 RNA <40 copies/mL; HBV DNA <14 IU/mL). a Seventy-six subjects (59% female) underwent assessment in July 2011 (T0), introduced tenofovir a median of 4 months later, and underwent a second assessment in July 2012 (T1). At T0, subjects had a median age of 40 years (IQR, 36-46 years) and 48 months of ART (IQR, 26-63 months). b The HBV drug resistance analysis (HBV DNA >100 IU/mL) comprised 28 subjects at T0 and 13 subjects at T1, and 27 and 12, respectively, yielded a sequence. c Only 2 of 11 subjects had new HBV RAMs (M204V + L180M) at T1, comprising compensatory mutations that restore viral fitness, explaining the high HBV DNA load measured in subjects with resistance. The patterns predicted cross-resistance to lamivudine, emtricitabine, telbivudine, and entecavir; 2 subjects showed A181S and A181T, which also confer resistance to adefovir and, to an extent, tenofovir. Thus, the majority of patients were expected to respond virologically to tenofovir. Indeed, after a median of 7.8 months of tenofovir, usually with ongoing lamivudine, both HBV DNA load and liver stiffness were reduced, and marked decreases were seen in those subjects who, pretenofovir, had shown high HBV DNA levels, the presence of HBV RAMs, and high TE measurements. The findings are thus consistent with studies in Western settings that used either liver biopsies or TE to monitor changes in fibrosis in patients with HBV or HIV/HBV coinfection receiving tenofovir [16] [17] [18] 28] . TE provides a simple and validated measure of liver fibrosis, with several advantages relative to biopsy including portability, increased volume of liver sampled, reduced diagnostic error in nonhomogenous fibrosis, and avoidance of adverse events [19-21, 28, 29] . We found that HBV DNA load was the factor most strongly associated with TE measurements. This is consistent with findings from ART-naive, HIV/HBV-coinfected subjects in Nigeria [22] . In HBV-infected subjects in Taiwan, HBV DNA load was similarly the strongest predictor of progression to cirrhosis over 11 years of follow-up [30] . AST levels and platelet counts and the APRI score were also associated with liver stiffness. An APRI cutoff score of 0.56 excluded TE measurements ≥9.4 kPa with a negative predictive value of 97%, which suggests utility as a screening tool. This finding requires confirmation. In previous studies in Burkina Faso, Cameroon, Cote d'Ivoire, Senegal, and Togo, HIV virologic failure rates ranged from 4% to 26% after 24-36 months of ART [31] . Long-term data are scarce. In the Kumasi cohort, the majority of patients were receiving NNRTI-based ART. After a median of 45 months of therapy, although immunologic responses were good, 21% of patients showed HIV-1 RNA levels >1000 copies/mL, the WHO-defined threshold for virologic failure, and at least 16% had drug resistance. In the absence of virologic monitoring, however, changes to PI-based ART were uncommon in routine practice. There was an association between HIV-1 RNA detection and HBV DNA detection, possibly reflecting inadequate compliance to ART and documenting overall poor therapeutic efficacy.
There are limitations to this study. Loss to follow-up is common in SSA, and our estimates are subject to survivorship and attrition bias; the rate of loss to follow-up is 10% per year in HEPIK. Although we reimbursed travel expenses, debilitated patients may have been unable to travel to clinic for TE. Sanger sequencing might have underestimated the prevalence of HIV and HBV drug resistance: we previously found that after just 6 months of lamivudine-containing ART, virtually all patients with persistent HBV viremia harbored M204I when tested by deep sequencing [8] . In this study, we were unable to use deep sequencing or sequence samples with HIV-1 RNA levels <200 copies/mL due to small volumes. As a consequence of limited local infrastructure, we had no assessment of treatment adherence and were unable to obtain liver biopsies, abdominal ultrasound scans, and more extensive biochemical panels to corroborate the TE findings. TE measurements may be falsely elevated in acute hepatitis, extrahepatic cholestasis, or, marginally, after a recent meal [32] . Only 1 patient had ALT levels more than twice above the upper limit, and excluding this patient did not affect the regression model (data not shown). ALT and AST were not markedly elevated, suggesting that HBV suppression is indeed the driver of improved TE measurements. We obtained bilirubin levels in 43 patients and none had raised values (data not shown). We did not require patients to attend for TE fasted, although scans took place in the mornings prior to lunch. Finally, we tested patients for HCV and HDV, but did not investigate other potential causes of liver disease (eg, schistosomiasis, alcohol abuse). Further studies are planned to ascertain the influence of these co-factors on liver disease in Ghana, and to measure the long-term efficacy of tenofovir.
Chronic viral hepatitis is a leading cause of morbidity and mortality in Western HIV-infected cohorts [33] . With expanded access to ART and reduced HIV-related mortality, there is potential for a high burden of liver disease to emerge in SSA, a risk amplified by high rates of HIV/HBV coinfection and lack of defined strategies for the diagnosis and management of viral hepatitis. Our findings that a substantial proportion of HIV/ HBV-coinfected subjects in Kumasi were at risk of progressive liver disease has led to the adoption of routine HBV screening in the HIV clinic, and HBV-coinfected patients have been prioritized for tenofovir use as it becomes more widely available. These developments, together with the early responses to tenofovir documented in the study, offer encouragement that improved control of HBV coinfection is an achievable goal across Africa.
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